Meeting
2015 Gastrointestinal Cancers Symposium
Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).
Authors
Edward Samuel James
Yale School of Medicine, New Haven, CT
Edward Samuel James , Xiangyu Cong , Xiaopan Yao , Carol Hahn , Kristin Kaley , Jia Li , Jeremy S. Kortmansky , Neal A. Fischbach , Charles Cha , Ronald R Salem , Stacey Stein , Howard S. Hochster , Jill Lacy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01523457
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 395)
DOI
10.1200/jco.2015.33.3_suppl.395
Abstract #
395
Poster Bd #
D14
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
First Author: Edward Samuel James
Poster
2016 ASCO Annual Meeting
Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
First Author: Makoto Ueno
Poster
2020 ASCO Virtual Scientific Program
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
First Author: Shintaro Nakano
Poster
2018 Gastrointestinal Cancers Symposium
Retrospective single center review of toxicity and efficacy of a modified FOLFIRINOX regimen in patients with locally advanced and metastatic pancreatic cancer.
First Author: Bhargavi Pulluri